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Evaluation), the Canadian guideline (Canadian Infectious
Disease Society), the US guideline (Infectious Diseases
Society of America), the South African guideline (South
African Drug Action Programme) and the Belgian guide-
line (Belgian Hygiene Committee) was assessed by an
independent investigator, according to the following 
criteria: antibiotic prophylaxis use, antimicrobial agent,
dosage of ﬁrst injection, time elapsed between ﬁrst injec-
tion and incision, total duration of antibiotic prophylaxis.
Interguideline agreement was assessed by using the Kappa
coefﬁcient. RESULTS: Overall compliance of physician
practice varied widely from 69% of patients for the 
Canadian guideline to 16% for the Belgian guideline
(compliance with the US guideline, the French guideline
and the South African guideline was respectively: 62%,
53% and 19%) (Kappa = 0.36; p < 0.01). These varia-
tions were principally due to the differences between
guidelines in the screening of Methicillin-Resistant
Staphylococcus aureus (MRSA) carriage and in the choice
of antimicrobial agent. CONCLUSIONS: Our ﬁndings
emphasize substantial discrepancies between national
guidelines from different countries. National experts
should take into account evidence-based data when
drawing up recommendations.
PIN13
CHANGES IN ANTIRETROVIRAL (ARV)
REGIMENS IN CLINICAL PRACTICE: RESULTS
FROM THE STAR (SCHEMAS THERAPEUTIQUES-
ANTIRETROVIRAUX) COHORT
Lilliu H1, Rozenbaum W2, Rafﬁ F3, Bugnon F3, Massip P4,
Foucher F5, Durand I6, Priol G1,Vincensini JP2, Le Pen C1
1Clp-santé, Paris, France; 2Hopital Tenon, Paris, France; 3CHRU
Nantes, Nantes, France; 4CHU Toulouse Hôpital Purpan,
Toulouse, France; 5GlaxoSmithKline, Marly-Le-Roi, France;
6Laboratory GSK, Marly-Le-Roi, France
OBJECTIVES: Although ﬁgures on the evolution of pre-
scriptions of ARV are now available, little is known about
the dynamics and reasons of treatment changes. The
STAR cohort was initiated in February 2001 across 3
French HIV Public Hospital to monitor and to explain
the evolution of ARV therapies. METHODS: STAR is an
observational study implemented to prospectively collect
electronic data on anti-HIV treatments, immunological
and virological status and medical cost of a random
sample of patients. It aims at identifying therapeutic
strategies in the setting of clinical practice. RESULTS: A
total of 1177 patients (77% male) were included, of mean
age 41 ± 9 years. A total of 290 patients (24.6%) had
clinical AIDS. Mean CD4 counts and viral load were
respectively 478 ± 275/mm3 and 29,300 ± 89,400
copies/ml in February 2001 versus 506 ± 283/mm3 and
15,300 ± 55,600 copies/ml in December 2002. Of the
whole cohort, 17% were ARV naïve in February 2001,
among whom 52.5% initiated an ARV treatment during
the observation period. The most frequent association in
February 2001 was 2 Nucleoside Reverse Transcriptase
Inhibitors (NRTI) + 1 Protease Inhibitor (PI) with 24.2%
of subjects, and in December 2002 2 NRTIs + 1 Non
Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
with 21.4%. Among emerging treatment schemes,
boosted PIs raised from 13.8% to 24.1%. Sixty percent
of patients had their regimen changed at least once over
the 21-month period. Main reasons of treatment changes
were toxicity (22%) and failure (21%). Among treatment
discontinuations, 32% were attributable to supervised
treatment interruption, 24% to toxicity and 14% to
patient’s decision. CONCLUSIONS: These preliminary
results obtained after 21 months of follow-up of the
STAR cohort show signiﬁcant trends in the changes of
treatment regimens with more simpliﬁed regimens and
more frequent multiple therapies. These ﬁndings could
help policy makers in the elaboration of guidelines and
the evaluation of adherence behavior.
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OBJECTIVE: This paper examines to analyze what deter-
mines the demand for vaccination in the elderly as a high
risk group. Then, by using the estimation results, this
paper evaluate how the law recommendation and/or
subsidy affect their demand. METHOD: Original data
were obtained from two surveys to the elders living with
descendants and the elders living without descendants,
conducted by the author. The survey contains the infor-
mation about the elders, the household, experience of
inﬂuenza during the last season and immunization during
and hypothetical questionnaire about immunization for
Conjoint Analysis. The three estimations are performed
for actual behavior; Conjoint Analysis and Joint Estima-
tion which combine the ﬁrst two estimation. RESULT:
Among estimation results, cost, number of immunization,
immunization in night or weekend, and law recommen-
dation heavily affect their demand. Experience of
inﬂuenza and immunization in the last season are the
most important determinants. Moreover, the superior of
the Joint Estimation is conﬁrmed. CONCLUSION: The
estimation results imply that about 8.9 million elders will
demand for vaccination if there is no cost and if there is
a law recommendation. Conversely, it will reduce to 3.2
million if cost is 6000yen (about $50 US dollars) and
without law recommendation. The change from no cost
to just 500yen (about $4 US dollars) depresses the
demand by 1.6 million elders. Law recommendation
alone can push up 2.0 million elders.
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OBJECTIVES: While information on the volume of
various drugs purchased by U.S. hospitals exists, infor-
mation on how hospitals actually utilize drugs is not
widely obtainable. We used inpatient transaction-level
data to investigate the association between patient char-
acteristics and treatment with selected anti-infective (AI)
drugs. We then applied this information to estimate AI
usage in a larger group of hospitals where no drug uti-
lization data were available. METHODS: We extracted
data for October 2000 through September 2001 from
Solucient’s Hospital Drug Utilization Database, which
contains patient-level demographic, clinical, and drug
information for 2.1 million inpatient discharges from 150
hospitals. Patients were classiﬁed into ﬁve clinical groups:
lower respiratory infection (LRI), septicemia, skin infec-
tion, urinary tract infection (UTI), and other. Separate
logistic regression models were ﬁtted for each group, with
patient characteristics as independent variables and use
of any of 20 common intravenous or oral AIs as the
outcome variable. We adjusted for principal diagnosis,
procedures, and interactions between principal and 
secondary diagnoses. Predictive accuracy was evaluated
using split-sample validation techniques. Coefﬁcients
from the regression models were then applied to records
of similar patients in Solucient’s Projected Inpatient 
Database, which contains 19 million hospital discharge
records annually but does not include drug data. We pro-
duced estimates of the probability of AI use for patients
in each clinical group at each hospital. RESULTS: Based
on split-sample methods, sensitivity ranged from 74.6%
for UTI to 90.9% for septicemia. Speciﬁcity ranged from
68.4% for LRI to 85.2% for the “other” category.
Percent correctly classiﬁed ranged from 74.7% for UTI
to 87.5% for septicemia. Interaction between principal
and secondary diagnosis codes was a strong predictor of
AI use. CONCLUSIONS: In inpatient data that lack
pharmaceutical information, use of selected anti-
infectives in these speciﬁc clinical groups can be predicted
with some accuracy based on patient characteristics.
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OBJECTIVE: To systematically review published eco-
nomic modeling studies directly comparing speciﬁc anti-
retroviral (ARV) drug treatment strategies. METHODS:
A systematic literature search using MEDLINE was con-
ducted of the English-language literature published
between 1995 and 2002 to capture modeling studies after
introduction of HAART using the following keywords:
AIDS, HIV, ARV, modeling, and costs. Manual searches
were also conducted of article bibliographies and other
relevant databases. Articles were excluded if they were
not direct drug comparisons (general HAART vs. no
HAART; PI class vs. NNRTI class). Factors including
model approaches, use of probabilistic sensitivity analy-
sis, and target audiences and journals were assessed.
RESULTS: Of >400 abstracts screened, only 38 articles
were identiﬁed as economic models of ARV therapy and
were reviewed in detail. Ten of these studies (6 US; 2 UK;
2 multi-country) directly compared speciﬁc ARV treat-
ments. Of these, 5 assessed cost-effectiveness over 
timeframes of 20–40 years, of which 2 also evaluated
cost-utility. The other 5 presented cost-consequence or
cost analysis with timeframes of 1 year in 4 of the studies.
Six studies compared zidovudine monotherapy to speciﬁc
combinations. Four studies used Markov modeling tech-
niques, while 3 used Monte Carlo simulation to test
uncertainty. Target audiences were typically the payer,
with one of the articles speciﬁcally tailored to a state
AIDS Drug Assistance Program perspective. Seven of the
studies were published in health economic or managed
care journals, and 3 published in therapeutic area-speciﬁc,
clinical journals. CONCLUSIONS: Economic models
comparing speciﬁc ARV treatments only represent ~25%
of published modeling studies in HIV/AIDS. Although
antiretroviral (ARV) therapies have been broadly reim-
bursed in the past, as more treatment options become
available, payers may increasingly require economic com-
parison of speciﬁc ARV drug treatment strategies. Until
recently, there has been widespread reimbursement of
HAART, which may explain the small number of head-
to-head economic modeling studies.
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OBJECTIVES: Pneumococcal disease is the leading cause
of bacterial infection in children, resulting in signiﬁcant
morbidity and mortality. In Canada, a heptavalent con-
jugate vaccine (PCV-7) aimed at preventing pneumococ-
cal diseases in children has been recommended by the
National Advisory Committee on Immunization. The
objective of this study was to identify value determinants,
both quantitative and qualitative, that contribute to the
societal beneﬁt of implementing a universal PCV-7
program. METHODS: Incidence rates and societal costs
were estimated for clinical and economic outcomes in
Canadian children less than ﬁve years of age: meningitis,
pneumonia, bacteremia, otitis media, and myringotomy.
These data were obtained primarily from a systematic
review of the literature on pneumococcal disease and
vaccine cost-beneﬁt using an OVID interface and included
the following databases: Pre-Medline, Medline and
EMBASE. The search was narrowed to studies of effec-
